Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

NCT02116777 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Adult Solid Neoplasm
Childhood Solid Neoplasm
Recurrent Childhood Central Nervous System Neoplasm
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Recurrent Malignant Solid Neoplasm
Refractory Central Nervous System Neoplasm

Interventions

OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Talazoparib
DRUG: Temozolomide

Sponsor

National Cancer Institute (NCI)